Dual inhibition of airway inflammation and fibrosis by common β cytokine receptor blockade.

Asthma CSL311 GM-CSF IL-3 IL-5 airway antibody biologic collagen common β cytokine eosinophils fibrosis hyperactivity inflammation macrophages neutrophils remodeling trabikibart

Journal

The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002

Informations de publication

Date de publication:
04 Nov 2023
Historique:
received: 25 03 2023
revised: 11 09 2023
accepted: 12 10 2023
pubmed: 7 11 2023
medline: 7 11 2023
entrez: 6 11 2023
Statut: aheadofprint

Résumé

Patients with severe asthma can present with eosinophilic type 2 (T2), neutrophilic, or mixed inflammation that drives airway remodeling and exacerbations and represents a major treatment challenge. The common β (βc) receptor signals for 3 cytokines, GM-CSF, IL-5, and IL-3, which collectively mediate T2 and neutrophilic inflammation. To determine the pathogenesis of βc receptor-mediated inflammation and remodeling in severe asthma and to investigate βc antagonism as a therapeutic strategy for mixed granulocytic airway disease. βc gene expression was analyzed in bronchial biopsy specimens from patients with mild-to-moderate and severe asthma. House dust mite extract and Aspergillus fumigatus extract (ASP) models were used to establish asthma-like pathology and airway remodeling in human βc transgenic mice. Lung tissue gene expression was analyzed by RNA sequencing. The mAb CSL311 targeting the shared cytokine binding site of βc was used to block βc signaling. βc gene expression was increased in patients with severe asthma. CSL311 potently reduced lung neutrophils, eosinophils, and interstitial macrophages and improved airway pathology and lung function in the acute steroid-resistant house dust mite extract model. Chronic intranasal ASP exposure induced airway inflammation and fibrosis and impaired lung function that was inhibited by CSL311. CSL311 normalized the ASP-induced fibrosis-associated extracellular matrix gene expression network and strongly reduced signatures of cellular inflammation in the lung. βc cytokines drive steroid-resistant mixed myeloid cell airway inflammation and fibrosis. The anti-βc antibody CSL311 effectively inhibits mixed T2/neutrophilic inflammation and severe asthma-like pathology and reverses fibrosis gene signatures induced by exposure to commonly encountered environmental allergens.

Sections du résumé

BACKGROUND BACKGROUND
Patients with severe asthma can present with eosinophilic type 2 (T2), neutrophilic, or mixed inflammation that drives airway remodeling and exacerbations and represents a major treatment challenge. The common β (βc) receptor signals for 3 cytokines, GM-CSF, IL-5, and IL-3, which collectively mediate T2 and neutrophilic inflammation.
OBJECTIVE OBJECTIVE
To determine the pathogenesis of βc receptor-mediated inflammation and remodeling in severe asthma and to investigate βc antagonism as a therapeutic strategy for mixed granulocytic airway disease.
METHODS METHODS
βc gene expression was analyzed in bronchial biopsy specimens from patients with mild-to-moderate and severe asthma. House dust mite extract and Aspergillus fumigatus extract (ASP) models were used to establish asthma-like pathology and airway remodeling in human βc transgenic mice. Lung tissue gene expression was analyzed by RNA sequencing. The mAb CSL311 targeting the shared cytokine binding site of βc was used to block βc signaling.
RESULTS RESULTS
βc gene expression was increased in patients with severe asthma. CSL311 potently reduced lung neutrophils, eosinophils, and interstitial macrophages and improved airway pathology and lung function in the acute steroid-resistant house dust mite extract model. Chronic intranasal ASP exposure induced airway inflammation and fibrosis and impaired lung function that was inhibited by CSL311. CSL311 normalized the ASP-induced fibrosis-associated extracellular matrix gene expression network and strongly reduced signatures of cellular inflammation in the lung.
CONCLUSIONS CONCLUSIONS
βc cytokines drive steroid-resistant mixed myeloid cell airway inflammation and fibrosis. The anti-βc antibody CSL311 effectively inhibits mixed T2/neutrophilic inflammation and severe asthma-like pathology and reverses fibrosis gene signatures induced by exposure to commonly encountered environmental allergens.

Identifiants

pubmed: 37931708
pii: S0091-6749(23)01394-5
doi: 10.1016/j.jaci.2023.10.021
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Hao Wang (H)

School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia.

Kwok Ho Yip (KH)

Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, Australia.

Simon P Keam (SP)

Research and Development, CSL Limited, Bio21 Molecular Science and Biotechnology Institute, Parkville, Australia.

Ross Vlahos (R)

School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia.

Kristy Nichol (K)

Immune Health Research Program, Hunter Medical Research Institute and University of Newcastle, Newcastle, Australia; Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia.

Peter Wark (P)

Immune Health Research Program, Hunter Medical Research Institute and University of Newcastle, Newcastle, Australia; Department of Respiratory and Sleep Medicine, John Hunter Hospital, Newcastle, Australia.

John Toubia (J)

Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, Australia.

Anita C Kral (AC)

Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, Australia.

Gökhan Cildir (G)

Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, Australia.

Harshita Pant (H)

Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, Australia; Faculty of Medicine, University of Adelaide, Adelaide, Australia.

Timothy R Hercus (TR)

Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, Australia.

Nick Wilson (N)

Research and Development, CSL Limited, Bio21 Molecular Science and Biotechnology Institute, Parkville, Australia.

Catherine Owczarek (C)

Research and Development, CSL Limited, Bio21 Molecular Science and Biotechnology Institute, Parkville, Australia.

Angel F Lopez (AF)

Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, Australia; Faculty of Medicine, University of Adelaide, Adelaide, Australia.

Steven Bozinovski (S)

School of Health and Biomedical Sciences, RMIT University, Bundoora, Australia. Electronic address: steven.bozinovski@rmit.edu.au.

Damon J Tumes (DJ)

Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, Australia. Electronic address: damon.tumes@unisa.edu.au.

Classifications MeSH